Heritage Trust Co raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,038 shares of the medical equipment provider’s stock after purchasing an additional 485 shares during the quarter. Heritage Trust Co’s holdings in Zimmer Biomet were worth $1,526,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of ZBH. Strs Ohio increased its stake in Zimmer Biomet by 20.9% during the 2nd quarter. Strs Ohio now owns 15,551 shares of the medical equipment provider’s stock valued at $1,996,000 after purchasing an additional 2,686 shares in the last quarter. CIBC Asset Management Inc increased its stake in Zimmer Biomet by 0.5% during the 2nd quarter. CIBC Asset Management Inc now owns 18,719 shares of the medical equipment provider’s stock valued at $2,404,000 after purchasing an additional 84 shares in the last quarter. Bessemer Group Inc. increased its stake in Zimmer Biomet by 21.1% during the 2nd quarter. Bessemer Group Inc. now owns 4,297 shares of the medical equipment provider’s stock valued at $552,000 after purchasing an additional 750 shares in the last quarter. Daiwa Securities Group Inc. increased its stake in Zimmer Biomet by 9.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 7,350 shares of the medical equipment provider’s stock valued at $944,000 after purchasing an additional 650 shares in the last quarter. Finally, Sei Investments Co. increased its stake in Zimmer Biomet by 11.6% during the 2nd quarter. Sei Investments Co. now owns 53,993 shares of the medical equipment provider’s stock valued at $6,932,000 after purchasing an additional 5,625 shares in the last quarter. Institutional investors and hedge funds own 86.24% of the company’s stock.

A number of research analysts have issued reports on the stock. Oppenheimer set a $137.00 price target on shares of Zimmer Biomet and gave the company a “buy” rating in a research note on Monday, August 14th. TheStreet downgraded shares of Zimmer Biomet from a “b-” rating to a “c+” rating in a report on Friday, November 24th. Gabelli initiated coverage on shares of Zimmer Biomet in a report on Thursday, August 24th. They issued a “buy” rating and a $142.00 price objective on the stock. SunTrust Banks reaffirmed a “buy” rating and issued a $136.00 price objective on shares of Zimmer Biomet in a report on Monday, October 2nd. Finally, Morgan Stanley dropped their price objective on shares of Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating on the stock in a report on Thursday, November 2nd. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $133.71.

Shares of Zimmer Biomet Holdings, Inc. (ZBH) traded up $0.67 during midday trading on Wednesday, reaching $115.49. 1,261,000 shares of the company were exchanged, compared to its average volume of 1,358,476. Zimmer Biomet Holdings, Inc. has a 12-month low of $100.69 and a 12-month high of $133.49. The stock has a market capitalization of $23,247.96, a P/E ratio of 14.23, a PEG ratio of 1.78 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The firm had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. During the same period last year, the company posted $1.79 earnings per share. The business’s quarterly revenue was down .8% on a year-over-year basis. equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.03 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/06/zimmer-biomet-holdings-inc-zbh-holdings-lifted-by-heritage-trust-co.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.